Drug Trial Radar · NCT02382276
A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence
Last checked: Nov 20, 2026Latest source record: Jul 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
405
Actual
Start
Jul 13, 2015
Primary completion
Jan 18, 2017
Study completion Jan 18, 2017
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.Otsuka
- Sponsor type
- Industry
- Collaborators
- H. Lundbeck A/S
- First posted
- Mar 6, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The long-term safety and efficacy of nalmefene hydrochloride at 20 mg in patients with alcohol dependence will be evaluated in a multicenter, open-label, uncontrolled trial.
Conditions
- Alcohol Dependence
Interventions
Nalmefene hydrochlorideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse EventsTime frame: 24-week treatment period
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Chubu
Region, Japan
Hokkaido
Region, Japan
Kanto
Region, Japan
Kinki
Region, Japan
Kyusyu
Region, Japan
Tohoku
Region, Japan
Tyugoku
Region, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.